Expression and Purification of scFv2H7-P18F3, a Bi-Modular Fusion Protein (BMFP) Targeting Human CD20
Open Access
- 1 January 2023
- journal article
- research article
- Published by Bio-Protocol, LLC in Bio-Protocol
- Vol. 13 (10)
Abstract
P18F3-based bi-modular fusion proteins (BMFPs), designed to re-direct pre-existing anti-Epstein-Barr virus (EBV) endogenous polyclonal antibodies towards defined target cells, demonstrated efficient biological activity in a mouse tumor model and could potentially represent a universal and versatile platform to develop novel therapeutics against a broad range of diseases. This protocol provides step-by-step instructions for expressing scFv2H7-P18F3, a BMFP targeting human CD20, in Escherichia coli (SHuffle®), and for purifying soluble proteins using a two-step process, namely immobilized metal affinity chromatography (IMAC) followed by size exclusion chromatography. This protocol can also be used for expression and purification of other BMFPs with alternative binding specificities.Keywords
This publication has 3 references indexed in Scilit:
- Monoclonal Antibodies in Cancer TherapyAntibodies, 2020
- Disulfide Bond Formation in the Bacterial Periplasm: Major Achievements and Challenges AheadAntioxidants & Redox Signaling, 2013
- SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasmMicrobial Cell Factories, 2012